Second Monoclonal Antibody to Prevent Malaria Shows Promise
-
A monoclonal antibody (mAb), L9LS, shows promise in preventing malaria infection, according to the results of a small, proof-of-concept study reported in The New England Journal of Medicine . Of 17 participants who received a single dose of L9LS in the phase 1 study, 15 (88%) were protected against malaria infection. In a similar small, phase 1 study reported last year, the monoclonal antibody CIS43LS showed promising results in providing protection. L9LS is three times more potent than CIS43, the parent antibody of CIS43LS.
-
@satish Malaria is the most common infectious cause of death in children younger than 5 years, killing one of them every minute; these early childhood deaths account for 80% of all malaria deaths. The recent RTS,S/AS01 vaccine (Mosquirix), recommended by the World Health Organization (WHO) last year for use among children, is a welcome advance but provides only about 36% protection after 4 years.